Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review
Open Access
- 23 September 2021
- journal article
- review article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (11) , 4457-4471
Abstract
Janus kinase (JAK) inhibitors have been developed as disease-modifying antirheumatic drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised regarding the risk of venous thromboembolism (VTE), such as deep vein thrombosis (DVT) and pulmonary embolism (PE). A recent post hoc safety analysis of placebo-controlled trials of JAK inhibitors in rheumatoid arthritis (RA) reported an imbalance in the incidence of VTE for a 4-mg daily dose of baricitinib versus placebo. In a recent postmarketing surveillance trial for RA, a significantly higher incidence of PE was reported in treatment with tofacitinib (10 mg twice daily) compared with tofacitinib 5 mg or tumor necrosis factor inhibitors. We also experienced a case of massive PE occurring 3 months after starting baricitinib (4 mg once daily) for multiple biologic-resistant RA. Nevertheless, the evidence to support the role of JAK inhibitors in VTE risk remains insufficient. There are a number of predisposing conditions and risk factors for VTE. In addition to the known risk factors that can provoke VTE, advanced age, obesity, diabetes mellitus, hypertension, hyperlipidemia, and smoking can also contribute to its development. Greater VTE risk is noted in patients with chronic inflammatory conditions, particularly RA patients with uncontrolled disease activity and any comorbidity. Prior to the initiation of JAK inhibitors, clinicians should consider both the number and strength of VTE risk factors for each patient. In addition, clinicians should advise patients to seek prompt medical help if they develop clinical signs and symptoms that suggest VTE/PE. Key Points• Patients with rheumatoid arthritis (RA) are at increased risk of venous thromboembolism (VTE), especially those with uncontrolled, high disease activity and those with comorbidities.• In addition to the well-known risk factors that provoke VTE events, advanced age and cardiovascular risk factors, such as obesity, diabetes mellitus, hypertension, hyperlipidemia, and smoking, should be considered risk factors for VTE.• Although a signal of VTE/pulmonary embolism (PE) risk with JAK inhibitors has been noted in RA patients who are already at high risk, the evidence is currently insufficient to support the increased risk of VTE during RA treatment with JAK inhibitors.• If there are no suitable alternatives, clinicians should prescribe JAK inhibitors with caution, considering both the strength of individual risk factors and the cumulative weight of all risk factors for each patient.Keywords
This publication has 82 references indexed in Scilit:
- Risk of Venous Thromboembolism in Patients With Rheumatoid ArthritisArthritis Care & Research, 2013
- Venous thromboembolism: Epidemiology and magnitude of the problemBest Practice & Research Clinical Haematology, 2012
- Triggers of Hospitalization for Venous ThromboembolismCirculation, 2012
- Heart Disease May Be a Risk Factor for Pulmonary Embolism Without Peripheral Deep Venous ThrombosisCirculation, 2011
- Noncardiac vascular disease in rheumatoid arthritis: Increase in venous thromboembolic events?Arthritis & Rheumatism, 2011
- Writing a narrative biomedical review: considerations for authors, peer reviewers, and editorsRheumatology International, 2011
- Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary HypertensionCirculation, 2011
- Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage studyBMC Medicine, 2011
- Incidence and mortality of venous thrombosis: a population‐based studyJournal of Thrombosis and Haemostasis, 2007
- Risk Factors for Venous ThromboembolismCirculation, 2003